Govt panel weighing risks and benefits of Merck's Covid drug

The Subject Expert Committee (SEC) under the drug regulator of India has asked manufacturers in India to specify the category of Covid patients that are likely to receive the greatest benefit of the treatment from the drug be indicated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3EEjKAN
via IFTTT